10000 Participants Needed

Registry for Hereditary Hemorrhagic Telangiectasia

(CHORUS Trial)

Recruiting at 17 trial locations
MA
NK
Overseen ByNolie Krock, MSc
Age: Any Age
Sex: Any
Trial Phase: Academic
Sponsor: Cure HHT
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to learn more about Hereditary Hemorrhagic Telangiectasia (HHT), a disorder that causes abnormal blood vessels and frequent nosebleeds. Researchers will gather information over time to understand how HHT affects individuals and identify factors that might alter the disease's progression. The goal is to improve future treatments for HHT. Anyone diagnosed with HHT, either through symptoms or genetic testing, and who can give consent, is eligible for this study. Participants will share their medical history and answer questions about their health annually. As an unphased study, this trial offers a unique opportunity to contribute to foundational research that could lead to a better understanding and treatment of HHT.

Why are researchers excited about this trial?

Researchers are excited about the Comprehensive HHT Outcomes Registry of the United States (CHORUS) because it aims to gather extensive data on Hereditary Hemorrhagic Telangiectasia (HHT), a condition often treated with a combination of medications, laser therapy, and, in severe cases, surgery. Unlike focusing on a single treatment, this registry allows for a comprehensive understanding of how different treatments and management strategies impact HHT over time. By collecting and analyzing data from a wide range of patients, CHORUS could lead to more personalized and effective treatment plans, filling knowledge gaps and potentially highlighting new therapeutic approaches. This holistic approach to studying HHT outcomes is what sets this initiative apart from traditional treatment studies.

Who Is on the Research Team?

MA

Melissa A Dickey, MSN

Principal Investigator

Cure HHT

Are You a Good Fit for This Trial?

Inclusion Criteria

I have been diagnosed with HHT either through specific criteria or genetic testing.
I can give my consent or have someone legally allowed to do it for me.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Data Collection

Comprehensive baseline clinical, demographic, and lifestyle data are collected using the HHT Baseline Assessment Scale

10 years
Annual visits (in-person or phone)

Longitudinal Data Collection

Prospective and retrospective data collection to assess clinical outcomes and disease progression using various assessment tools

10 years
Annual visits (in-person or phone)

Follow-up

Participants are monitored for changes in health, new test results, treatment information, symptoms, and complications from HHT

10 years
Annual visits (in-person or phone)

What Are the Treatments Tested in This Trial?

Find a Clinic Near You

Who Is Running the Clinical Trial?

Cure HHT

Lead Sponsor

Trials
4
Recruited
10,400+

Children's Hospital of Philadelphia

Collaborator

Trials
749
Recruited
11,400,000+

University of Alabama at Birmingham

Collaborator

Trials
1,677
Recruited
2,458,000+

University of California, San Francisco

Collaborator

Trials
2,636
Recruited
19,080,000+

Mayo Clinic

Collaborator

Trials
3,427
Recruited
3,221,000+

University of California, Los Angeles

Collaborator

Trials
1,594
Recruited
10,430,000+

The Cleveland Clinic

Collaborator

Trials
1,072
Recruited
1,377,000+

University of Pennsylvania

Collaborator

Trials
2,118
Recruited
45,270,000+

Washington University School of Medicine

Collaborator

Trials
2,027
Recruited
2,353,000+

University of North Carolina, Chapel Hill

Collaborator

Trials
1,588
Recruited
4,364,000+